News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
News
Top ASX 200 stocks: These 12 companies have gained over 1000pc in 5 years
News
Here are the top ASX large cap movers for Thursday
News
Here are the top ASX large cap movers for Monday
Health & Biotech
ScoPo’s Powerplays: Market volatility creates both buying and selling opportunities in the Health sector
Health & Biotech
ASX Health Stocks: Imugene granted Japan patent, share price is now up 50% in a month
News
Here are the top ASX large cap movers for Friday
Health & Biotech
ASX Health Stocks: Imugene up on PD1-Vaxx cancer study expansion plans
News
Here are the top ASX large cap movers for Thursday
Health & Biotech
ScoPo’s Powerplays: Profit-taking on the cards for health stocks that have had good runs
Health & Biotech
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space
Health & Biotech
Australian biotech figurehead Paul Hopper raises $20 million for his latest pre-IPO venture
Health & Biotech
ScoPo’s Powerplays: Smaller capped health stocks are still in ‘no man’s land’, but Neuren jumps 18pc this week
Health & Biotech
ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
News
ASX Capital Raise Roundup: Plenty of activity to report but IPOs remain weak
News
Here are the Top 25 ASX large cap movers for Thursday
News